As an independent student newspaper and the paper of record for the city of Berkeley, the Daily Cal has been communicating important updates during this pandemic. Your support is essential to maintaining this coverage.
UC Berkeley professor of molecular and cell biology and of chemistry Jennifer Doudna has been awarded the 2020 Wolf Prize in Medicine for her discovery of CRISPR-Cas9 gene-editing tool.
Read More…
The UC system was awarded a patent Tuesday, marking the university’s 16th patent for the CRISPR-Cas9 patent portfolio — the highest number in the country.
Read More…
The UC system and partners University of Vienna and Emmanuelle Charpentier were awarded a 12th patent for the CRISPR-Cas9 gene-editing technology.
Read More…
The UC’s family of eight patents covers CRISPR methods for editing genes in any environment, whether the cells are in a plant, an animal or a human. This newest patent focuses specifically on the use of CRISPR gene editing within cells.
Read More…
The U.S. Patent and Trademark Office granted the University of California a new patent for the revolutionary CRISPR-Cas9 system of gene-editing technology on Tuesday. The patent, No. 10,301,651, covers methods of modulating DNA transcription.
Read More…
On April 23, the U.S. Patent and Trademark Office issued UC Berkeley its fourth patent for CRISPR Cas-9, a revolutionary gene-editing technology.
Read More…
UC Berkeley announced Tuesday that the U.S. Patent and Trademark Office has granted a patent to CRISPR, a gene-editing technology.
Read More…
Campus molecular biology and biochemistry professor Jennifer Doudna was awarded the American Cancer Society’s Medal of Honor on Oct. 18 for her role in developing CRISPR-Cas9, a revolutionary gene-editing technology.
Read More…
Campus molecular biology and biochemistry professor Jennifer Doudna was awarded the 2018 Kavli Prize in nanoscience for her role in discovering CRISPR, a revolutionary gene-editing technology, in a gala hosted by Norwegian King Harald V on Tuesday.
Read More…
The U.S. Patent Trial and Appeal Board ruled there was no interference between the patents requested by Broad Institute and the University of California regarding CRISPR technology, prompting the UC system to consider further legal steps to secure patent rights over the use of CRISPR-Cas9 in all types of cells and organisms.
Read More…
